All In Biotech

Drug Trial Radar · NCT06337318

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 23, 2024

Primary completion

Mar 31, 2032

Study completion Mar 31, 2032

Sponsor

Sponsor type
NIH
First posted
Mar 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Conditions

  • Classic Follicular Lymphoma
  • Follicular Lymphoma With Unusual Cytological Features

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT and/or PET/CT scan

  • MosunetuzumabBiological

    Given SC

  • Positron Emission TomographyProcedure

    Undergo PET/CT scan

  • RituximabBiological

    Given IV

  • Rituximab and Hyaluronidase HumanBiological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year milestone progression free survival (PFS)Time frame: From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 3 years
  2. PFSTime frame: From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 10 years

Locations

289 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Recruiting

  • City of Hope Antelope Valley

    Lancaster, California · Recruiting

  • City of Hope at Long Beach Elm

    Long Beach, California · Recruiting

  • Tibor Rubin VA Medical Center

    Long Beach, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • City of Hope South Pasadena

    South Pasadena, California · Recruiting

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California · Recruiting

  • City of Hope Upland

    Upland, California · Recruiting

  • UCI Health - Yorba Linda

    Yorba Linda, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Poudre Valley Hospital

    Fort Collins, Colorado · Recruiting

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado · Recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado · Recruiting

  • Medical Center of the Rockies

    Loveland, Colorado · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Suspended

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Aventura

    Aventura, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Coral Springs

    Coral Springs, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Doral

    Doral, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Hollywood

    Hollywood, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida · Recruiting

  • Mount Sinai Medical Center

    Miami Beach, Florida · Recruiting

Showing 40 of 289 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.